Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (10): 985-992.DOI: 10.3969/j.issn.1673-8640.2024.10.010
Previous Articles Next Articles
ZHU Yanyan, YAN Zelin, WU Yuchen, ZHANG Yanyan, ZHANG Rong()
Received:
2023-11-25
Revised:
2024-05-14
Online:
2024-10-30
Published:
2024-11-08
CLC Number:
ZHU Yanyan, YAN Zelin, WU Yuchen, ZHANG Yanyan, ZHANG Rong. Epidemiology,drug resistance and virulence gene analysis of Clostridium perfringens in different populations[J]. Laboratory Medicine, 2024, 39(10): 985-992.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.10.010
基因名称 | 前向引物序列(5'~3') | 反向引物序列(5'~3') | 产物长度/bp | 熔解温度/℃ |
---|---|---|---|---|
cpa | GCTAATGTTACTGCCGTTGA | CCTCTGATACATCGTGTAAG | 324 | 55 |
cpb | GCGAATATGCTGAATCATCTA | GCAGGAACATTAGTATATCTTC | 196 | 50 |
cpb2 | GATTTTAAATATGATCCTAAC | CAATACCCTTCACCAAATACTC | 567 | 55 |
cpe | GGAGATGGTTGGATATTAGG | GGACCAGCAGTTGTAGATA | 233 | 55 |
etx | TGGGAACTTCGATACAAGCA | TTAACTCATCTCCCATAACTGCAC | 396 | 50 |
iap | AAACGCATTAAAGCTCACACC | CTGCATAACCTGGAATGGCT | 293 | 50 |
netB | CTTCTAGTGATACCGCTTCAC | CGTTATATTCACTTGTTGACGAAAG | 738 | 50 |
基因名称 | 前向引物序列(5'~3') | 反向引物序列(5'~3') | 产物长度/bp | 熔解温度/℃ |
---|---|---|---|---|
cpa | GCTAATGTTACTGCCGTTGA | CCTCTGATACATCGTGTAAG | 324 | 55 |
cpb | GCGAATATGCTGAATCATCTA | GCAGGAACATTAGTATATCTTC | 196 | 50 |
cpb2 | GATTTTAAATATGATCCTAAC | CAATACCCTTCACCAAATACTC | 567 | 55 |
cpe | GGAGATGGTTGGATATTAGG | GGACCAGCAGTTGTAGATA | 233 | 55 |
etx | TGGGAACTTCGATACAAGCA | TTAACTCATCTCCCATAACTGCAC | 396 | 50 |
iap | AAACGCATTAAAGCTCACACC | CTGCATAACCTGGAATGGCT | 293 | 50 |
netB | CTTCTAGTGATACCGCTTCAC | CGTTATATTCACTTGTTGACGAAAG | 738 | 50 |
患者类型 | 例数 | 年龄/岁 | 性别 | 抗菌药物使用(入院后) | |||
---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | 有/[例(%)] | 无/[例(%)] | ||||
短期住院患者 | 59 | 50.5±41.5 | 38(64.41) | 21(35.59) | 0(0) | 59(100) | |
长期住院患者 | 36 | 38.5±26.5 | 21(58.33) | 15(41.67) | 36(100) | 0(0) | |
统计值 | 6.706 | 0.280 | 95.000 | ||||
P值 | <0.001 | 0.597 | <0.001 |
患者类型 | 例数 | 年龄/岁 | 性别 | 抗菌药物使用(入院后) | |||
---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | 有/[例(%)] | 无/[例(%)] | ||||
短期住院患者 | 59 | 50.5±41.5 | 38(64.41) | 21(35.59) | 0(0) | 59(100) | |
长期住院患者 | 36 | 38.5±26.5 | 21(58.33) | 15(41.67) | 36(100) | 0(0) | |
统计值 | 6.706 | 0.280 | 95.000 | ||||
P值 | <0.001 | 0.597 | <0.001 |
组别 | MIC范围 | MIC50/(µg·mL-1) | MIC90/(µg·mL-1) | 耐药率/[株/株(%)] | 敏感率/[株/株(%)] |
---|---|---|---|---|---|
甲硝唑 | |||||
健康体检者 | 0.5->32 | 4 | >32 | 23/125(18.4) | 99/125(79.2) |
短期住院患者 | 0.5->32 | 4 | 32 | 8/59(13.6) | 47/59(83.1) |
长期住院患者 | 1->32 | 4 | >32 | 8/36(22.2) | 25/36(69.5) |
环丙沙星 | |||||
健康体检者 | 0.125->32 | 0.25 | 0.5 | 1/125(0.8) | 124/125(99.2) |
短期住院患者 | 0.125->32 | 0.25 | 0.5 | 3/59(5.1) | 56/59(94.9) |
长期住院患者 | 0.125->32 | 0.25 | 0.5 | 1/36(2.8) | 35/36(97.2) |
青霉素 | |||||
健康体检者 | 0.064-2 | 0.125 | 0.5 | 1/125(0.8) | 117/125(93.6) |
短期住院患者 | <0.064-4 | 0.125 | 0.5 | 1/59(1.6) | 56/59(94.9) |
长期住院患者 | <0.064-2 | 0.125 | 0.5 | 2/36(5.6) | 34/36(94.4) |
阿莫西林 | |||||
健康体检者 | <0.064-0.25 | <0.064 | 0.25 | ||
短期住院患者 | <0.064-1 | <0.064 | 0.25 | ||
长期住院患者 | <0.064-0.25 | <0.064 | 0.25 | ||
四环素 | |||||
健康体检者 | <0.064->256 | 8 | 16 | 39/125(31.2) | 35/125(28.0) |
短期住院患者 | <0.064-128 | 8 | 16 | 19/59(32.2) | 10/59(16.9) |
长期住院患者 | <0.064-64 | 8 | 16 | 15/36(41.7) | 10/36(27.8) |
头孢西丁 | |||||
健康体检者 | 0.5-8 | 1 | 2 | 0/125(0.0) | 125/125(100.0) |
短期住院患者 | 0.5-256 | 1 | 2 | 1/59(1.7) | 58/59(98.3) |
长期住院患者 | 0.25-8 | 1 | 4 | 0/36(0.0) | 36/36(100.0) |
利奈唑胺 | |||||
健康体检者 | 0.5-2 | 1 | 2 | 0/125(0.0) | 125/125(100.0) |
短期住院患者 | 1-2 | 1 | 2 | 0/59(0.0) | 59/59(100.0) |
长期住院患者 | 1-8 | 2 | 2 | 1/36(2.7) | 35/36(97.2) |
克林霉素 | |||||
健康体检者 | <0.064->256 | 4 | >256 | 62/125(49.6) | 46/125(36.8) |
短期住院患者 | <0.064->256 | 8 | >256 | 31/59(52.5) | 18/59(30.5) |
长期住院患者 | 0.064->256 | >256 | >256 | 20/36(55.6) | 9/36(25.0) |
红霉素 | |||||
健康体检者 | 1->256 | >256 | >256 | 75/125(60.0) | 0/125(0.0) |
短期住院患者 | 1->256 | >256 | >256 | 37/59(62.7) | 0/59(0.0) |
长期住院患者 | 1->256 | >256 | >256 | 20/36(55.6) | 0/36(0.0) |
组别 | MIC范围 | MIC50/(µg·mL-1) | MIC90/(µg·mL-1) | 耐药率/[株/株(%)] | 敏感率/[株/株(%)] |
---|---|---|---|---|---|
甲硝唑 | |||||
健康体检者 | 0.5->32 | 4 | >32 | 23/125(18.4) | 99/125(79.2) |
短期住院患者 | 0.5->32 | 4 | 32 | 8/59(13.6) | 47/59(83.1) |
长期住院患者 | 1->32 | 4 | >32 | 8/36(22.2) | 25/36(69.5) |
环丙沙星 | |||||
健康体检者 | 0.125->32 | 0.25 | 0.5 | 1/125(0.8) | 124/125(99.2) |
短期住院患者 | 0.125->32 | 0.25 | 0.5 | 3/59(5.1) | 56/59(94.9) |
长期住院患者 | 0.125->32 | 0.25 | 0.5 | 1/36(2.8) | 35/36(97.2) |
青霉素 | |||||
健康体检者 | 0.064-2 | 0.125 | 0.5 | 1/125(0.8) | 117/125(93.6) |
短期住院患者 | <0.064-4 | 0.125 | 0.5 | 1/59(1.6) | 56/59(94.9) |
长期住院患者 | <0.064-2 | 0.125 | 0.5 | 2/36(5.6) | 34/36(94.4) |
阿莫西林 | |||||
健康体检者 | <0.064-0.25 | <0.064 | 0.25 | ||
短期住院患者 | <0.064-1 | <0.064 | 0.25 | ||
长期住院患者 | <0.064-0.25 | <0.064 | 0.25 | ||
四环素 | |||||
健康体检者 | <0.064->256 | 8 | 16 | 39/125(31.2) | 35/125(28.0) |
短期住院患者 | <0.064-128 | 8 | 16 | 19/59(32.2) | 10/59(16.9) |
长期住院患者 | <0.064-64 | 8 | 16 | 15/36(41.7) | 10/36(27.8) |
头孢西丁 | |||||
健康体检者 | 0.5-8 | 1 | 2 | 0/125(0.0) | 125/125(100.0) |
短期住院患者 | 0.5-256 | 1 | 2 | 1/59(1.7) | 58/59(98.3) |
长期住院患者 | 0.25-8 | 1 | 4 | 0/36(0.0) | 36/36(100.0) |
利奈唑胺 | |||||
健康体检者 | 0.5-2 | 1 | 2 | 0/125(0.0) | 125/125(100.0) |
短期住院患者 | 1-2 | 1 | 2 | 0/59(0.0) | 59/59(100.0) |
长期住院患者 | 1-8 | 2 | 2 | 1/36(2.7) | 35/36(97.2) |
克林霉素 | |||||
健康体检者 | <0.064->256 | 4 | >256 | 62/125(49.6) | 46/125(36.8) |
短期住院患者 | <0.064->256 | 8 | >256 | 31/59(52.5) | 18/59(30.5) |
长期住院患者 | 0.064->256 | >256 | >256 | 20/36(55.6) | 9/36(25.0) |
红霉素 | |||||
健康体检者 | 1->256 | >256 | >256 | 75/125(60.0) | 0/125(0.0) |
短期住院患者 | 1->256 | >256 | >256 | 37/59(62.7) | 0/59(0.0) |
长期住院患者 | 1->256 | >256 | >256 | 20/36(55.6) | 0/36(0.0) |
样本编号 | 共与CRO检出 菌株名称 | 样本性状 | 碳青霉烯酶 类型 | 抗菌药物使用情况 |
---|---|---|---|---|
1 | 大肠杆菌 | 稀 | NDM | 头孢他啶、美罗培南、头孢哌酮-舒巴坦、亚胺培南、依替米星、哌拉西林他唑巴坦、万古霉素、左氧氟沙星、替加环素、复方磺胺甲噁唑、甲硝唑 |
鲍曼不动杆菌 | 稀 | OXA-23 | ||
2 | 大肠杆菌 | 稀 | NDM | 莫西沙星、头孢唑肟、左氧氟沙星、头孢地嗪、头孢哌酮-舒巴坦 |
3 | 神户肠杆菌 | 软 | NDM | 哌拉西林-他唑巴坦、头孢他啶、拉氧头孢 |
铜绿假单胞菌 | 软 | 未检出 | ||
4 | 铜绿假单胞菌 | 稀 | 未检出 | 左氧氟沙星、拉氧头孢、左氧氟沙星、哌拉西林-他唑巴坦 |
5 | 肺炎克雷伯菌 | 稀 | NDM | 伏立康唑 |
6 | 铜绿假单胞菌 | 软 | 未检出 | 头孢唑肟、莫西沙星、头孢羟羧氧 |
7 | 大肠埃希菌 | 软 | KPC | 哌拉西林-他唑巴坦、莫西沙星、头孢唑肟、左氧氟沙星、头孢哌酮-舒巴坦、头孢地嗪、阿奇霉素、替硝唑、美罗培南、甲硝唑 |
8 | 大肠埃希菌 | 糊 | KPC | 头孢唑肟、美罗培南、莫西沙星、替加环素、氟康唑、亚胺培南、左氧氟沙星、多黏菌素、哌拉西林-他唑巴坦、头孢哌酮-舒巴坦、头孢地嗪 |
依替米星 | ||||
9 | 铜绿假单胞菌 | 稀 | 未检出 | 头孢哌酮-舒巴坦、氟康唑、头孢羟羧氧、甲硝唑、头孢唑肟、万古霉素、头孢他啶、哌拉西林-他唑巴坦 |
鲍曼不动杆菌 | 稀 | OXA-23 |
样本编号 | 共与CRO检出 菌株名称 | 样本性状 | 碳青霉烯酶 类型 | 抗菌药物使用情况 |
---|---|---|---|---|
1 | 大肠杆菌 | 稀 | NDM | 头孢他啶、美罗培南、头孢哌酮-舒巴坦、亚胺培南、依替米星、哌拉西林他唑巴坦、万古霉素、左氧氟沙星、替加环素、复方磺胺甲噁唑、甲硝唑 |
鲍曼不动杆菌 | 稀 | OXA-23 | ||
2 | 大肠杆菌 | 稀 | NDM | 莫西沙星、头孢唑肟、左氧氟沙星、头孢地嗪、头孢哌酮-舒巴坦 |
3 | 神户肠杆菌 | 软 | NDM | 哌拉西林-他唑巴坦、头孢他啶、拉氧头孢 |
铜绿假单胞菌 | 软 | 未检出 | ||
4 | 铜绿假单胞菌 | 稀 | 未检出 | 左氧氟沙星、拉氧头孢、左氧氟沙星、哌拉西林-他唑巴坦 |
5 | 肺炎克雷伯菌 | 稀 | NDM | 伏立康唑 |
6 | 铜绿假单胞菌 | 软 | 未检出 | 头孢唑肟、莫西沙星、头孢羟羧氧 |
7 | 大肠埃希菌 | 软 | KPC | 哌拉西林-他唑巴坦、莫西沙星、头孢唑肟、左氧氟沙星、头孢哌酮-舒巴坦、头孢地嗪、阿奇霉素、替硝唑、美罗培南、甲硝唑 |
8 | 大肠埃希菌 | 糊 | KPC | 头孢唑肟、美罗培南、莫西沙星、替加环素、氟康唑、亚胺培南、左氧氟沙星、多黏菌素、哌拉西林-他唑巴坦、头孢哌酮-舒巴坦、头孢地嗪 |
依替米星 | ||||
9 | 铜绿假单胞菌 | 稀 | 未检出 | 头孢哌酮-舒巴坦、氟康唑、头孢羟羧氧、甲硝唑、头孢唑肟、万古霉素、头孢他啶、哌拉西林-他唑巴坦 |
鲍曼不动杆菌 | 稀 | OXA-23 |
[1] | MEHDIZADEH GOHARI I, A NAVARRO M, LI J, et al. Pathogenicity and virulence of Clostridium perfringens[J]. Virulence, 2021, 12(1):723-753. |
[2] | GRENDA T, JAROSZ A, SAPAŁA M, et al. Clostridium perfringens-opportunistic foodborne pathogen,its diversity and epidemiological significance[J]. Pathogens, 2023, 12(6):768. |
[3] | HEIDA F H, VAN ZOONEN A G J F, HULSCHER J B F, et al. A necrotizing enterocolitis-associated gut microbiota is present in the meconium:results of a prospective study[J]. Clin Infect Dis, 2016, 62(7):863-870. |
[4] | VAN BUNDEREN C C, BOMERS M K, WESDORP E, et al. Clostridium perfringens septicaemia with massive intravascular haemolysis:a case report and review of the literature[J]. Neth J Med, 2010, 68(9):343-346. |
[5] | YANG Z, HU J, QU Y, et al. Interventions for treating gas gangrene[J]. Cochrane Database Syst Rev, 2015, 2015(12):CD010577. |
[6] | GIBERT M, JOLIVET-REYNAUD C, POPOFF M R. Beta2 toxin,a novel toxin produced by Clostridium perfringens[J]. Gene, 1997, 203(1):65-73. |
[7] | CAI J, SCHWARZ S, CHI D, et al. Faecal carriage of optrA-positive enterococci in asymptomatic healthy humans in Hangzhou,China[J]. Clin Microbiol Infect, 2019, 25(5):630. |
[8] | Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement[S]. M100-S18,CLSI, 2008. |
[9] | Clinical Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria[S]. M11-Ed9,CLSI, 2018. |
[10] |
ROOD J I, ADAMS V, LACEY J, et al. Expansion of the Clostridium perfringens toxin-based typing scheme[J]. Anaerobe, 2018, 53:5-10.
DOI PMID |
[11] | BHATTACHARYA A, SHANTIKUMAR S, BEAUFOY D, et al. Outbreak of Clostridium perfringens food poisoning linked to leeks in cheese sauce:an unusual source[J]. Epidemiol Infect, 2020, 148:e43. |
[12] | CARMAN R J, SAYEED S, LI J, et al. Clostridium perfringens toxin genotypes in the feces of healthy North Americans[J]. Anaerobe, 2008, 14(2):102-108. |
[13] | YADAV J P, KAUR S, DHAKA P, et al. Prevalence,molecular characterization,and antimicrobial resistance profile of Clostridium perfringens from India:a scoping review[J]. Anaerobe, 2022, 77:102639. |
[14] | HEINZE K, KABETO M, MARTIN E T, et al. Predictors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization among nursing facility patients[J]. Am J Infect Control, 2019, 47(4):415-420. |
[15] | HUANG C, FENG S, HUO F, et al. Effects of four antibiotics on the diversity of the intestinal microbiota[J]. Microbiol Spectr, 2022, 10(2):e0190421. |
[16] | NG K M, FERREYRA J A, HIGGINBOTTOM S K, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens[J]. Nature, 2013, 502(7469):96-99. |
[17] | WANG Y H. Sialidases from Clostridium perfringens and their inhibitors[J]. Front Cell Infect Microbiol, 2020, 9:462. |
[18] | MANTZARLIS K, MAKRIS D, ZAKYNTHINOS E. Risk factors for the first episode of Acinetobacter baumannii resistant to colistin infection and outcome in critically ill patients[J]. J Med Microbiol, 2020, 69(1):35-40. |
[19] | EIMER J, FRÉCHET-JACHYM M, LE DÛ D, et al. Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment[J]. Clin Infect Dis, 2023, 76(3):e947-e956. |
[20] | GARVEYM. Foodborne clostridioides species:pathogenicity,virulence and biocontrol options[J]. Microorganisms, 2023, 11(10):2483. |
[21] | UZAL F A, NAVARRO M A, ASIN J, et al. Clostridial diarrheas in piglets:a review[J]. Vet Microbiol, 2023, 280:109691. |
[22] | LI J, ZHOU Y, YANG D, et al. Prevalence and antimicrobial susceptibility of Clostridium perfringens in chickens and pigs from Beijing and Shanxi,China[J]. Vet Microbiol, 2020, 252:108932. |
[23] | LENCER W I. Everything illuminated-Clostridium perfringens β-toxin[J]. Cell Host Microbe, 2020, 28(1):5-6. |
[24] | CAMARGO A, RAMÍREZ J D, KIU R, et al. Unveiling the pathogenic mechanisms of Clostridium perfringens toxins and virulence factors[J]. Emerg Microbes Infect, 2024, 13,(1):2341968. |
[25] | TOOTH D, GARSED K, SINGH G, et al. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea:origin and effect of gut transit[J]. Gut, 2014, 63(5):753-760. |
[26] | FOHLER S, KLEIN G, HOEDEMAKER M, et al. Diversity of Clostridium perfringens toxin-genotypes from dairy farms[J]. BMC Microbiol, 2016, 16(1):199. |
[27] | XIU L, LIU Y, WU W, et al. Prevalence and multilocus sequence typing of Clostridium perfringens isolated from 4 duck farms in Shandong province,China[J]. Poult Sci, 2020, 99(10):5105-5117. |
[28] | 李红新, 卢迎瑞, 张爽, 等. 北京市顺义区87名健康人中产气荚膜梭菌携带特征研究[J]. 中国食品卫生杂志, 2019, 31(1):13-16. |
[29] | WANG B, DONG W, MA L, et al. Prevalence and genetic diversity of Clostridium perfringens isolates in hospitalized diarrheal patients from central China[J]. Infect Drug Resist, 2021, 14:4783-4793. |
[30] | BALKAN I I, AYGÜN G, AYDIN S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae:treatment and survival[J]. Int J Infect Dis, 2014, 26:51-56. |
[1] | GUO Chaonan, WANG Yanyan, ZHANG Bei, PANG Jingying, CUI Feifei, ZHAO Yongxin, SU Bing. Analysis of drug resistance and virulence of Klebsiella pneumoniae from different clinical samples [J]. Laboratory Medicine, 2024, 39(9): 880-887. |
[2] | YU Feng, HU Longhua, XIAO Yanping, YANG Junping. Virulence genes and molecular characteristics of Klebsiella pneumoniae isolated from bloodstream infection patients [J]. Laboratory Medicine, 2024, 39(3): 249-255. |
[3] | ZHU Yurong, ZHANG Dan, HE Yaxing, LI Jingjing, HUANG Jing, LI Ting, LIU Peng, LIU Ronghua. Classification and epidemiology characteristics of Klebsiella pneumoniae isolated from clinic [J]. Laboratory Medicine, 2023, 38(5): 435-440. |
[4] | FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361. |
[5] | PAN Yunqi, LI Yungai, WANG Jianqiang, WU Qiong, TANG Jin. Analysis of molecular typing,virulence genes and antibiotic susceptibility of uropathogenic Escherichia coli in patients with recurrent urinary tract infection [J]. Laboratory Medicine, 2022, 37(2): 141-145. |
[6] | KANG Yi, ZHU Hong, SHEN Han, ZHOU Wanqing. Virulence gene analysis of Enterococcus isolated from clinical blood and urine samples [J]. Laboratory Medicine, 2022, 37(11): 1030-1033. |
[7] | GUO Wei, HUANG Jianghua, WU Bei, CHEN Fang, HE Xiaohua. Drug resistance and virulence distribution characteristics of clinical isolates of Enterococcus in a hospital [J]. Laboratory Medicine, 2020, 35(12): 1267-1271. |
[8] | XIE Hongyi, YE Hongyan, ZHOU Fangman, SHI Lumei, GE Tingting, LE Xubo. Virulence genes and drug resistance of Vibrio parahaemolyticus isolated from patients with diarrhea in Ningbo [J]. Laboratory Medicine, 2019, 34(2): 136-139. |
[9] | HUANG Chunlan, XU Qiuhong, YU Hongli, MA Limei, LIAO Zhihong. Characteristics and whole-genome sequencing of 1 isolate of Campylobacter coil from blood [J]. Laboratory Medicine, 2019, 34(12): 1091-1096. |
[10] | DAI Sui. Invasion abilities and the virulence gene expressions of Salmonella typhimurium with different origins [J]. Laboratory Medicine, 2017, 32(2): 71-75. |
[11] | HU Binjie, ZHAO Fuju, WANG Shiwen, XIANG Ping, YANG Changqing, FANG Yi, CHEN Fei, YANG Feng, ZHAO Hu, ZHANG Yanmei. Correlation of Helicobacter pylori virulence genotypes and clinical characteristics [J]. Laboratory Medicine, 2016, 31(6): 479-485. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||